Alterity Financial Statements From 2010 to 2026

ATHE Stock  USD 3.30  0.15  4.35%   
Alterity Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Alterity Therapeutics' valuation are provided below:
Gross Profit
5.3 M
Profit Margin
(2.23)
Market Capitalization
62.5 M
Enterprise Value Revenue
113.9898
Revenue
5.4 M
There are over one hundred nineteen available fundamental signals for Alterity Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Alterity Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 20, 2026, Market Cap is expected to decline to about 47.5 M. In addition to that, Enterprise Value is expected to decline to about 31.2 M

Alterity Therapeutics Total Revenue

6.57 Million

Check Alterity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alterity Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.9 K, Other Operating Expenses of 24.2 M or Total Operating Expenses of 24 M, as well as many indicators such as Price To Sales Ratio of 10.06, Dividend Yield of 0.0 or PTB Ratio of 1.43. Alterity financial statements analysis is a perfect complement when working with Alterity Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Alterity Stock
Check out the analysis of Alterity Therapeutics Correlation against competitors.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

Alterity Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets55.6 M52.9 M29.1 M
Slightly volatile
Cash40 M38.1 M22.4 M
Slightly volatile
Cash And Short Term Investments49.1 M46.8 M23.8 M
Slightly volatile
Common Stock Shares Outstanding12.9 M12.3 M3.6 M
Slightly volatile
Liabilities And Stockholders Equity55.6 M52.9 M29.1 M
Slightly volatile
Total Liabilities2.6 M4.2 M3.2 M
Slightly volatile
Total Current Assets55.4 M52.8 M29 M
Slightly volatile
Common Stock317.5 M302.4 M174 M
Slightly volatile
Other Current Liabilities1.7 M3.4 M2.2 M
Slightly volatile
Total Current Liabilities2.8 M4.1 M3.2 M
Slightly volatile
Property Plant And Equipment Net108.5 K178.4 K104.5 K
Slightly volatile
Accounts PayableM619 K898.3 K
Slightly volatile
Non Current Assets Total132.7 K139.7 K922.5 K
Slightly volatile
Net Receivables2.5 M4.5 M3.5 M
Slightly volatile
Other Current Assets750.1 K1.5 M991 K
Slightly volatile
Common Stock Total Equity128.1 M227.1 M153 M
Slightly volatile
Non Current Liabilities Total68.4 K79.7 K36.8 K
Slightly volatile
Property Plant And Equipment Gross174.3 K178.4 K191.8 K
Slightly volatile
Other Liabilities15 K22.4 K12 K
Slightly volatile
Net Tangible Assets24.6 M26.2 M21.7 M
Slightly volatile
Property Plant Equipment324.7 K309.2 K130.9 K
Slightly volatile
Net Invested Capital25.5 M48.8 M25 M
Slightly volatile
Net Working Capital25.4 M48.7 M24.9 M
Slightly volatile
Capital Stock224.5 M302.4 M188.7 M
Slightly volatile

Alterity Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses24.2 M23 M13.9 M
Slightly volatile
Total Revenue6.6 M6.3 M2.2 M
Slightly volatile
Research Development8.5 M16.6 M10.8 M
Slightly volatile
Depreciation And Amortization24.2 K25.5 K98.2 K
Slightly volatile
Selling General Administrative3.7 M4.9 M4.4 M
Pretty Stable
Interest Income500.3 K401.7 K1.6 M
Slightly volatile
Net Interest Income538.9 K513.2 K180 K
Slightly volatile
Reconciled Depreciation86.1 K160.7 K63.5 K
Slightly volatile

Alterity Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.4 M14.5 M18.6 M
Pretty Stable
Depreciation194 K125.7 K135.6 K
Pretty Stable
End Period Cash Flow40 M38.1 M22.6 M
Slightly volatile
Issuance Of Capital Stock51.4 M49 M19.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.0610.59153
Slightly volatile
Days Sales Outstanding2262384.2 K
Slightly volatile
Average Payables705.4 K503.7 K871.2 K
Slightly volatile
Capex To Depreciation0.03320.03490.6463
Slightly volatile
Sales General And Administrative To Revenue1.11.1610.8094
Slightly volatile
Research And Ddevelopement To Revenue2.262.3828.1295
Slightly volatile
Capex To Revenue0.00160.00160.0737
Slightly volatile
Cash Per Share0.00690.00730.0251
Slightly volatile
Income Quality0.750.851.0122
Pretty Stable
Intangibles To Total Assets0.30.320.3107
Slightly volatile
Net Debt To EBITDA2.172.591.7865
Very volatile
Current Ratio6.3811.688.6181
Very volatile
Receivables Turnover1.511.591.6176
Slightly volatile
Debt To Equity0.0040.00420.0125
Slightly volatile
Capex Per Share0.00.01.0E-4
Slightly volatile
Average ReceivablesM5.7 M4.4 M
Slightly volatile
Revenue Per Share9.0E-40.0010.0011
Pretty Stable
Interest Debt Per Share0.00.03.0E-4
Slightly volatile
Debt To Assets0.00370.00390.0099
Slightly volatile
Operating Cycle2262385.4 K
Slightly volatile
Ebt Per Ebit1.130.950.9616
Very volatile
Total Debt To Capitalization0.0040.00420.012
Slightly volatile
Debt Equity Ratio0.0040.00420.0125
Slightly volatile
Quick Ratio6.3411.688.5714
Very volatile
Net Income Per E B T0.80.910.9705
Slightly volatile
Cash Ratio7.4810.797.126
Very volatile
Days Of Sales Outstanding2262384.2 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0188
Slightly volatile
Fixed Asset Turnover33.1231.5517.0314
Slightly volatile
Debt Ratio0.00370.00390.0099
Slightly volatile
Price Sales Ratio10.0610.59153
Slightly volatile
Asset Turnover0.110.11820.0676
Slightly volatile

Alterity Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap47.5 M73.6 M45 M
Pretty Stable

Alterity Fundamental Market Drivers

About Alterity Therapeutics Financial Statements

Alterity Therapeutics stakeholders use historical fundamental indicators, such as Alterity Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Alterity Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Alterity Therapeutics' assets and liabilities are reflected in the revenues and expenses on Alterity Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Alterity Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue14.4 K13.7 K
Total Revenue6.3 M6.6 M
Cost Of Revenue146.7 K154 K
Stock Based Compensation To Revenue 0.21  0.20 
Sales General And Administrative To Revenue 1.16  1.10 
Research And Ddevelopement To Revenue 2.38  2.26 
Ebit Per Revenue(3.08)(3.24)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:
Check out the analysis of Alterity Therapeutics Correlation against competitors.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.61)
Revenue Per Share
0.6
Quarterly Revenue Growth
0.809
Return On Assets
(0.28)
Return On Equity
(0.43)
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.